Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.47 |
| ▸ | MEN1 | O00255 | 5/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | GSTO1 | P78417 | 3/20 | 0.42 |
| ▸ | CPB1 | P15086 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3451487 | 0.88 | KMT2A (0.54) | NPSR1KMT2AMEN1L3MBTL1HTT | |
| SCHEMBL3909417 | 0.84 | KMT2A (0.49) | NPSR1KMT2AMEN1L3MBTL1HTT | |
| SCHEMBL3909391 | 0.82 | NPSR1 (0.49) | NPSR1KMT2AMEN1L3MBTL1HTT | |
| SCHEMBL3917014 | 0.81 | KMT2A (0.45) | NPSR1KMT2AMEN1L3MBTL1HTT | |
| SCHEMBL3918686 | 0.79 | FFAR1 (0.52) | NPSR1KMT2AMEN1MAPT | |
| SCHEMBL1746924 | 0.79 | KMT2A (0.52) | NPSR1KMT2AMEN1L3MBTL1HTT | |
| SCHEMBL1744789 | 0.76 | KMT2A (0.54) | NPSR1KMT2AMEN1L3MBTL1HTT | |
| SCHEMBL18423708 | 0.75 | FAAH (0.43) | KMT2AL3MBTL1MAPTRAB9AFAAH | |
| SCHEMBL3917024 | 0.75 | NPSR1 (0.53) | NPSR1KMT2AMEN1L3MBTL1HTT | |
| SCHEMBL1747338 | 0.74 | KMT2A (0.56) | NPSR1KMT2AMEN1L3MBTL1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1698624-B1 | PHENYLPROPANOIC ACID DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2012-06-27 | — | — | EP | disclosed |
| US-7585880-B2 | Phenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585880-B2 | Phenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-08 | — | — | US | disclosed |
| US-7585880-B2 | Phenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-09-08 | — | — | US | disclosed |
| US-20070155808-A1 | Phenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20070155808-A1 | Phenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | US | disclosed |
| US-20070155808-A1 | Phenylpropanoic acid derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-07-05 | — | — | US | disclosed |
| EP-1698624-A1 | PHENYLPROPANOIC ACID DERIVATIVES | Takeda Pharmaceutical Company Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070155808-A1 | Phenylpropanoic acid derivatives | GPR119, GPR55, FFAR1 | NPSR1 169/4885KMT2A 3549/4885MEN1 2970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.